Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 14, 2025Cancer Immunology ImmunotherapyOpen Access

Tertiary lymphoid structures gene signature predicts response to immunotherapy plus chemotherapy in advanced non-small cell lung cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

WDWei DuBXBijing XiaoXYXuan Yang

Discussion

Loading...

Member takes

Overview

This analysis identifies TLS-derived gene signature in advanced NSCLC patients, suggesting improved predictions for CIT response.

Key Points

  • TLS signature 3 predicts longer progression-free survival in advanced NSCLC patients receiving CIT, enhancing treatment strategies.
  • High signature 3 scores correlate with significantly better overall survival rates compared to low scores in advanced lung cancer patients.
  • The developed nomogram integrating signature 3 effectively discriminates patient outcomes, indicating its clinical relevance in treatment planning.
  • Signature 3's predictive value extends to PD-L1-negative patients, highlighting its potential as a complementary biomarker for immunotherapy.

Cite This Study

Du et al. (2025) studied this question.

synapsesocial.com/papers/68d42047713b0b5dfea68ba7https://doi.org/10.1007/s00262-025-04165-2
View Full Paper
Ask AI
Bookmark
Share